NIH Meeting Funds Diabetes, Digestive, and Kidney Disease Research
Published Date: 3/24/2025
Notice
Summary
The National Institute of Diabetes and Digestive and Kidney Diseases is holding a meeting on April 24, 2025, to review and decide on grant applications that support research in diabetes, digestive, and kidney diseases. The meeting is partly open to the public but includes private sessions to protect sensitive information. Researchers and organizations applying for grants should note this important date as it impacts funding decisions.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Grant Review and Funding Decisions
The National Institute of Diabetes and Digestive and Kidney Diseases will review and decide on grant applications on April 24, 2025. Researchers and organizations applying for grants should note this date because the meeting directly impacts which grant applications receive funding.
Public Attendance Is Limited
Part of the April 24, 2025 meeting is open to the public from 4:00 p.m. to 4:30 p.m., but attendance is limited to space available. If you plan to attend and need accommodations like sign language interpretation, you should notify the listed contact person in advance.
Confidentiality for Grant Applicants
Portions of the April 24, 2025 meeting will be closed (e.g., 4:35 p.m.–5:05 p.m. and 5:10 p.m.–5:30 p.m.) to protect confidential trade secrets, patentable material, and personal information in grant applications. Grant applicants have their proprietary and personal information protected during those closed sessions.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2025-04909, Polypropylene Corrugated Boxes From China and Vietnam; Institution of Antidumping and Countervailing Duty Investigations and Scheduling of Preliminary Phase Investigations
The U.S. is launching investigations to see if cheap polypropylene corrugated boxes from China and Vietnam are hurting American businesses. If these boxes are found to be unfairly priced or subsidized, extra taxes might be added to protect U.S. makers. The first big decision is expected by May 2, 2025, so things are moving fast!
Next: 2025-04912, National Institute of Environmental Health Sciences; Notice of Meeting
The National Institute of Environmental Health Sciences is holding a hybrid meeting from May 4-6, 2025, where experts will review grant applications and discuss important research. The public can join some sessions online or in person, but some parts are private to protect personal info. This meeting affects researchers seeking funding and helps decide who gets support for environmental health studies.